1. Ramishetti S., and Peer D. (2018) Engineering lymphocytes with RNAi. Advanced Drug Delivery Reviews PDF
  2. Rosenblum D., Joshi N., Tao W., Karp J.M.,  Peer D. (2018) Progress and challenges towards targeted delivery of cancer therapeutics. Nature Communications 9, 1-12. PDF
  3. Granot Y. and Peer D (2017) Delivering the right message: challenges and opportunities in lipid nanoparticles-mediated modified mRNA therapeutics- An innate immune system standpoint. Semin Immunol. PDF
  4. Rietwyk S., Peer D.(2017) Next-Generation Lipids in RNA Interference Therapeutics. ACS Nano 11, 7572−7586. PDF 
  5. Alvarez M.M., Aizenberg J., Analoui M., Andrews A.M., Bisker G., Boyden E.S , Kamm R.D., Karp j.M., Mooney D.J., Oklu R., Peer D., Stolzoff M.,  Strano M.S.,  Trujillo-de Santiago G., Webster T.J., Weiss P.S., Khademhosseini A. (2017) Emerging trends in Micro- and nanoscale technologies in medicine: from basic discoveries to translation. ACS Nano 11, 5195-5214. PDF
  6. Mizrahy S, Hazan-Halevy I, Dammes N, Landesman-Milo D, Peer D. (2017) Current Progress in Non-viral RNAi-Based Delivery Strategies to Lymphocytes.Molecular Therapy 25, 1491-1500. PDF
  7. Mizrahy S., Hazan-Halevy I., Landesman-Milo D. and  Peer D. (2017) Advanced strategies in immune modulation of cancer using lipid-based nanoparticles. Frontiers in Immunology 8, 69. PDF
  8. Anchordoquy T. J.,  Barenholz Y.,  Boraschi D., Chorny M.,  Decuzzi P., . Dobrovolskaia M.A, Farhangrazi Z. S.,  Farrell D., Gabizon A., Ghandehari H.,  Godin B.,  La-Beck N. M., Ljubimova J., Moghimi S.M., Pagliaro L.,  Park J.H.,  Peer D., Ruoslahti E., Serkova N.J., and Simber D. (2017) Mechanisms and barriers in cancer nanomedicine: addressing challenges, looking for solutions. ASC Nano.  PDF
  9. Ng B.D. and Peer D. (2017) Orchestrating a symphony on a single conjugate: aptamer targeting, gene silencing, and immunomodulation to enhance antitumor response. Molecular Therapy 25, 5-7. PDF
  10. Hazan-Halevy I. , Landesman-Milo D., Rosenblum D. , Mizrahy S., Ng B.D., and Peer D. (2016) Immunomodulation of hematological malignancies using oligonucleotides based-nanomedicines. Journal of Controlled Release, 244, 149-156. PDF
  11. Gutkin A., Cohen ZR, and Peer D. (2016) Harnessing nanomedicine for therapeutic intervention in glioblastoma. Expert Opinion on Drug Delivery ISSN: 1742-5247. PDF
  12. Ramishetti S, Landesman-Milo D, Peer D. (2016) Advances in RNAi therapeutic delivery to leukocytes using lipid nanoparticles. Journal of Drug Target 30, 1-6. PDF
  13. Singh M.S., Peer D. (2016) siRNA delivery:Current trends and future perspectives. Ther. Delivery 7(2), 52-53. PDF
  14. Singh M.S., Peer D. (2016) RNA nanomedicines: the next generation drugs? Current Opinion in Biotechnology 28-34PDF
  15. Landesman-Milo D, Peer D. (2016) Transforming nanomedicines from lab scale production to novel clinical modality. Bioconjug Chem. 27, 855-862. PDF
  16. Moyano DF., Liu Y., Peer D. and Rotello VM. (2016) Modulation of immune response using engineered nanoparticle surfaces. Small 12(1),76-82. PDF
  17. Moghimi SM., Hunter AC., Peer D. (2016) Platelet mimicry: The emperor's new clothes? Nanomedicine 12, 245-248. PDF
  18. Landesman-Milo D., Ramishetti S. and Peer D. (2015) Nanomedicine as an emerging platform for metastatic lung cancer therapy. Cancer and Metastasis Reviews 34(2), 291-301. PDF
  19. Ganoth A, Cohen K.M, and Peer D (2015) Overcoming multidrug resistance with drug delivery strategies. Expert Opinion on Drug Delivery 12(2), 223-338. PDF
  20. Peer D. (2014) Precision medicine - delivering the goods? Cancer Letters 352, 2-3. PDF
  21. Goldsmith M., Abramovitz L., and Peer D (2014) Precision nanomedicine in neurodegenerative diseases. ACS Nano 8(3), 1958-1965. PDF
  22. Bogart L.K., Pourroy G., Murphy C,J., Puntes V.F., Pellegrino T., Rosenblum D., Peer D.*, and Lévy R* (2014) Nanoparticles for imaging, sensing, and therapeutic intervention. ACS Nano 8(4), 3107–3122. *denotes equal contribution. PDF 
  23. Peer D (2014) Harnessing RNAi nanomedicine for precision therapy. Molecular and Cellular Therapies 2(5), 2-11. PDF
  24. Rosenblum D. and Peer D (2014) Omics-based nanomedicine: The future of personalized oncology. Cancer Letters. 352, 126-136. PDF
  25. Peer D, Giannechi N. and Luo D. (2013) Nanoparticles in biology. Journal of Materials Chemistry BPDF
  26. Mizrahy S., Landesman-Milo D., and Peer D (2013) Sweet fairytale: carbohydrates as backbones for glyconanomedicine. Israel Journal of Chemistry 53 (9-10), 616-629. PDF
  27. Howard KA. and Peer D. (2013) Providing the full picture: a mandate for standardizing nanoparticle-based drug delivery. Nanomedicine (Lond.) 8 (7), 1-3. PDF
  28. Peer D. (2013) A daunting task: manipulating leukocyte function with RNAi. Immunol Rev. 253, 185-197.PDF
  29. Vorup-Jensen T, Peer D. (2012) Nanotoxicity and the importance of being earnest. Adv. Drug Deliv. Rev. 64 (15) 1661-1662. PDF
  30. Daka A, Peer D. (2012) RNAi-based nanomedicines for targeted personalized therapy. Adv. Drug Deliv. Rev. 64(13), 1508-1521. PDF
  31. Peer D. (2012) Immunotoxicity derived from manipulating leukocytes with lipid-based nanoparticles. Adv. Drug Deliv. Rev. 64 (15), 1738–1748. PDF
  32. Barenholz Y, and Peer D (2012) Liposomes, lipid biophysics, and sphingolipid research: from basic to translation research. Chemistry & Physics of Lipids 165, 363-364. PDF
  33. Barenholz Y, Peer D. (2012) Liposomes and other assemblies as drugs and nano-drugs: from basic and translational research to the clinics. Journal of Controlled Release 160(2), 115-116. PDF
  34. Landsman–Milo D, Peer D (2012) Altering the immune response with liposomes. Journal of Controlled Release 161, 600-608. PDF
  35. Mizrahy S, Peer D (2012). Polysaccharides as building blocks for nanotherapeutics. Chem. Soc. Rev. 41, 2623–2640. PDF
  36. Goldsmith M, Mizrahy S, Peer D (2011) Grand challenges in modulating the immune response with RNAi Nanomedicines. Nanomedicine 6(10), 1771-1785. PDF
  37. Peer D, Lieberman J. (2011) Special delivery: targeted therapy with small RNAs. Gene therapy 18(12), 1127-1133. PDF
  38. Elfakess R, Peer D. (2010) Overcoming RNAi transduction in leukocytes using targeted and stabilized nanoparticles. IDrugs 13(9), 626-631. PDF
  39. Weinstein S., and Peer D (2010) RNAi Nanomedicines: challenges and within opportunities the immune system. Nanotechnology 21(23), 232001, 1-13. PDF
  40. Peer D. (2010) Induction of therapeutic gene silencing in leukocyte-implicated diseases by targeted and stabilized nanoparticles: a mini-review. Journal of Controlled Release. 148(1), 63-68. PDF
  41. Kedmi R, and Peer D (2009) RNAi nanoparticles in the service of personalized medicine. Nanomedicine 4(8), 853-855. PDF
  42. Peer D, and Shimaoka M (2009) Systemic siRNA delivery to leukocyte-implicated diseases. Cell Cycle 8, 853-859. PDF
  43. Peer D, Karp JM, Hong S, Farokhzad O, Margalit R, and Langer R (2007) Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology 2, 751-760. PDF
  44. Klausner EA, Peer D, Chapman RL, Multack RF, Andurkar SV. (2007) Corneal gene therapy. Journal of Controlled Release 124(3), 107-133. PDF
  45. Peer D, and Margalit R (2006) Fluoxetine and reversal of multidrug resistance. Cancer Letters 237,180-187. PDF